Literature DB >> 7525523

Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

M Toi1, S Hoshina, T Takayanagi, T Tominaga.   

Abstract

Angiogenesis is an independent prognostic indicator in breast cancer. In this report, the relationship between expression of vascular endothelial growth factor (VEGF; a selective mitogen for endothelial cells) and the microvessel density was examined in 103 primary breast cancers. The expression of VEGF was evaluated by immunocytochemical staining using anti-VEGF antibody. The microvessel density, which was determined by immunostaining for factor VIII antigen, in VEGF-rich tumors was clearly higher than that in VEGF-poor tumors (P < 0.01). There was a good correlation between VEGF expression and the increment of microvessel density. Furthermore, postoperative survey demonstrated that the relapse-free survival rate of VEGF-rich tumors was significantly worse than that of VEGF-poor tumors. It was suggested that the expression of VEGF is closely associated with the promotion of angiogenesis and with early relapse in primary breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525523      PMCID: PMC5919354          DOI: 10.1111/j.1349-7006.1994.tb02904.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  20 in total

1.  Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways.

Authors:  K P Claffey; W O Wilkison; B M Spiegelman
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

2.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

3.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

4.  Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.

Authors:  S Kondo; M Asano; H Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1993-08-16       Impact factor: 3.575

5.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

Authors:  C K Goldman; J Kim; W L Wong; V King; T Brock; G Y Gillespie
Journal:  Mol Biol Cell       Date:  1993-01       Impact factor: 4.138

6.  Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

Authors:  A Osaki; M Toi; H Yamada; H Kawami; K Kuroi; T Toge
Journal:  Am J Surg       Date:  1992-10       Impact factor: 2.565

7.  Microvessel quantitation and prognosis in invasive breast carcinoma.

Authors:  S Bosari; A K Lee; R A DeLellis; B D Wiley; G J Heatley; M L Silverman
Journal:  Hum Pathol       Date:  1992-07       Impact factor: 3.466

8.  Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth.

Authors:  K Cullinan-Bove; R D Koos
Journal:  Endocrinology       Date:  1993-08       Impact factor: 4.736

9.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

Authors:  E R Horak; R Leek; N Klenk; S LeJeune; K Smith; N Stuart; M Greenall; K Stepniewska; A L Harris
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

10.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

Authors:  C de Vries; J A Escobedo; H Ueno; K Houck; N Ferrara; L T Williams
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

View more
  69 in total

Review 1.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.

Authors:  Y X Yin; F Shen; H Pei; Y Ding; Hua Zhao; Min Zhao; Q Chen
Journal:  Tumour Biol       Date:  2012-05-30

Review 3.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

4.  Targeted Therapy: Can It Substitute for Chemotherapy?

Authors:  Florian Schütz
Journal:  Breast Care (Basel)       Date:  2008-08-20       Impact factor: 2.860

5.  Computational modeling on the recognition of the HRE motif by HIF-1: molecular docking and molecular dynamics studies.

Authors:  Pandian Sokkar; Vani Sathis; Murugesan Ramachandran
Journal:  J Mol Model       Date:  2011-08-05       Impact factor: 1.810

Review 6.  The role of angiogenic growth factors in breast cancer progression.

Authors:  F G Kern; M E Lippman
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

7.  What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?

Authors:  R F Nicosia
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

Review 8.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.

Authors:  S B Fox; A L Harris
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

9.  Diversity of the angiogenic phenotype in non-small cell lung cancer.

Authors:  Marc R McClelland; Shannon L Carskadon; Liujian Zhao; Eric S White; David G Beer; Mark B Orringer; Allan Pickens; Andrew C Chang; Douglas A Arenberg
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

10.  Does CD34 Staining Reflect the Angiogenic Process in the Bone Marrow? An Analysis of a Series of Chronic Myeloid Leukemia Patients.

Authors:  Krishnan Kulumani Mahadevan; Debdatta Basu; Swarup Kumar
Journal:  J Clin Diagn Res       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.